Skip to content

The effect of flaxseed on the quality of life, mental health and clinical symptoms of people with migraine

The effect of flaxseed on the quality of life, mental health and clinical symptoms of people with migraine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230616058497N1
Enrollment
100
Registered
2023-07-08
Start date
2023-08-23
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine

Interventions

Intervention 1: Intervention group: The intervention process will be as follows: for a period of 2 months, the intervention group will be given 20 grams of seeds per day. Intervention 2: Control group

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Suffering from a migraine confirmed by a neurologist based on the criteria of the third edition of the International Classification of Headache Disorder The participants must be between 18 and 50 years old At least 1 year has passed since their illness They have not started complementary treatments (such as biofeedback) Do not have thyroid and digestive disorders Willing to participate in the study

Exclusion criteria

Exclusion criteria: Women who are pregnant or breastfeeding People who suffer from other chronic diseases (such as: kidney). Those who take certain nutritional supplements that may affect migraines such as (coenzyme Q10, riboflavin, magnesium). Those who take omega-3 supplements Those who have a history of allergy to flax seeds

Design outcomes

Primary

MeasureTime frame
Assess the severity of migraine. Timepoint: Measurement at the beginning of the study, 30 and 60 days after the start of the study. Method of measurement: The visual Analog Scale for pain (VAS).

Secondary

MeasureTime frame
Examining people's condition in terms of depression, stress and anxiety. Timepoint: First study, 30 and 60 days after the intervention. Method of measurement: In order to check the condition of people in terms of depression, stress and anxiety, the 21-question DASS questionnaire modified for Iran is used.;Sleep quality. Timepoint: First study, 30 and 60 days after the intervention. Method of measurement: The sleep quality of the participants is measured by the Insomnia Severity Index (ISI) questionnaire.;Quality of Life. Timepoint: First study, 30 and 60 days after the intervention. Method of measurement: In order to evaluate the level of disability caused by migraine, the Headache Impact Test-6 questionnaire is used.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmirhosein Jafarpour

Shiraz University of Medical Sciences

ahj1376@gmail.com+98 71 3725 1001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026